Market Capitalization

CEO Werner Lanthaler will present FairJourney Bio's data-driven antibody discovery platform at the elite J.P. Morgan conference, signaling major growth.

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

The shipping giant cashes in on eight older vessels, using a massive profit to slash debt, reward shareholders, and accelerate its sustainable fleet strategy.

CEO Joe Hayek will outline a strategy of M&A and innovation to boost value as the company navigates a complex market. Here’s what to expect.

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.

NRG Energy names insider Robert J. Gaudette as its next CEO, signaling strategic continuity as the energy giant navigates a market in transformation.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

Facing declining revenue but armed with a strong AI vision, Unisys CEO Mike Thomson prepares to address investors at the critical Needham Growth Conference.

Amid rising geopolitical risks, Taiwan's J-Star is exiting China to build an automated factory in the US, a bold move for the micro-cap company.

With AI reshaping cybersecurity, Ping Identity appoints Adnan Chaudhry as CRO to scale its trusted identity solutions for a new digital landscape.

CleanSpark boosts Bitcoin output by over 10% and pivots to AI data centers, all while helping stabilize the power grid in times of extreme demand.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

Limbach Holdings appoints M&A and operations expert Terry Dugan to its board, a strategic move aimed at accelerating growth in mission-critical markets.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

Solmate Infrastructure appoints financial heavyweight Erez Simha to its board, bolstering its ambitious plan to build a Solana hub in Abu Dhabi.